Industry Reports
Amid Global Setbacks, Indian Pharma Exports Grow In 2021-22
The Government of India recently announced that the pharmaceutical sector had its best-ever export performance in 2021-22, with a phenomenal increase of about $10 billion in just eight years. Since 2013-14, the country's pharmaceutical sector has grown by 103%, from...
Industry Reports
Samsung Biologics Reports First Quarter 2022 Financial Results
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.
John Rim, CEO of Samsung Biologics, stated, “Samsung Biologics’ strong start to the 2022 fiscal year was driven...
Industry Reports
Tong Ren Tang Technologies Co. Ltd. Strong Performance Revenue 5.4billion and Net Profit 867million in 2021
With the strong support and promotion of the government, the traditional Chinese medicine industry has inherited from the tradition and developed innovatively and rapidly. 2021 is the revolutionary year of Tong Ren Tang Technologies (01666). The company achieved excellent...
Industry Reports
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021.
John Rim, CEO of Samsung Biologics, stated, “With a steep increase in demand...
Industry Reports
Botanical Solution Inc Secures $6.1 Million in Series A First Closing
Botanical Solution Inc. (BSI), innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round...
Industry Reports
MasterControl Announces Annual Recurring Revenue Milestone
MasterControl, a global provider of software solutions for life sciences and other regulated industries, announced it has reached $100 million in annual recurring revenue (ARR), led by their signature software solutions, Quality Excellence and Manufacturing Excellence, as well as...
Drug Research
Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services
Aragen Life Sciences (formerly, GVK BIO), a leading partner offering R&D and Manufacturing solutions (CRO/CDMO) for life sciences industries worldwide, expects high teens growth in 2022, with NCE development and manufacturing business growing at circa 40% year-on-year.
The company, states...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read